Cannabidiol for marijuana abuse

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 15 Feb 2024: Trial registered, NCT06261489
  2. 5 Dec 2025: Trial started, NCT06261489

The trials

NCT05885542: SCORE Emerging Adult Cannabis Use & Stress

State
Under way
Phase
Phase 1 and Phase 2
People
148 planned
Started
1 Nov 2023
Primary completion
31 Jul 2028
Arms
cannabidiol 800 mg
Results
None posted
  1. 2 Jun 2023: Trial registered
  2. 1 Nov 2023: Trial started

NCT06261489: Cannabis (THC vs. CBD) in Multiple Sclerosis

State
Under way
Phase
Phase 2
People
30 planned
Started
5 Dec 2025
Primary completion
30 Sep 2027
Arms
Cannabidiol (CBD) 50 mg
Results
None posted
  1. 15 Feb 2024: Trial registered
  2. 5 Dec 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Cardiolrx, Canapure PH, Cannabidiol (Epidiolex), Cannabidiol Oral Solution, Epidiolex, Epidiolex 100 mg/mL Oral Solution, Epidyolex, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose, GWP42003-P 5 mg/kg/day Dose, MediCabilis.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.